Clinical trials: Rectal Cancer, Radiotherapy
Colorectal Cancer
Combination Chemotherapy and Bevacizumab With or Without Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, fluorouracil, and leucovorin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00462501
- Testing
- bevacizumab, fluorouracil, leucovorin calcium
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Colorectal Cancer
Low and Intermediate Risk OliGometastatic ColoREctal CancEr PatieNts Treated with Stereotactic ABlative Radiotherapy
This is an experimental study without drug or device, randomized, open-label, non-profit, sponsored by the IRCCS Sacro Cuore Don Calabria Hospital in Negrar, which will take place at the Department of Advanced Oncological…
- Trial name
- GREENLaIT-SABR (NCT06310564)
- Testing
- SABR
- Where
- Italy
- Volunteers
- 204 people
- Sponsor
- IRCCS Sacro Cuore Don Calabria di Negrar
Metastatic Colorectal Cancer
Assess the Efficacy of Pembrolizumab Plus Radiotherapy or Ablation in Metastatic Colorectal Cancer Patients
The radiation therapy or ablation that the patient received as standard therapy treated only the tumors that were radiated or ablated.
- Trial name
- NCT02437071
- Testing
- Pembrolizumab, Radiotherapy, Radiofrequency ablation
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Anal Cancer, Recurrent Anal Cancer
Pencil Beam Proton Therapy for Recurrences in Anal Cancer Patients Previously Treated With Radiotherapy (DACG 5)
This protocol aims to determine toxicity and efficacy of re-irradiation for patients with recurrences from anal cancers with dose-escalated pencil beam proton therapy either pre-operative for marginally resectable recurrences or…
- Trial name
- ReRad III (NCT05055635)
- Testing
- Pencil beam proton therapy
- Where
- Denmark
- Volunteers
- 55 people
- Sponsor
- University of Aarhus
Castration-Resistant Prostate Carcinoma, Metastatic Colorectal Carcinoma
Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial
This trial compares cryoablation combined with stereotactic body radiation therapy to stereotactic body radiation therapy alone to see how well they work in treating patients with pain from cancer that has spread to the bones…
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT04693377
- Testing
- Cryosurgery, Quality-of-Life Assessment, Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Rectal Cancer
Palliative Radiochemotherapy Against Palliative Surgery in Stage IV Rectal Cancer With Unresectable Metastases
Short course palliative radiotherapy (5x5Gy)to the pelvis in patients with symptomatic rectal tumours and with unresectable metastases may prevent palliative surgery with a good palliative outcome.The consolidating chemotherapy…
- Trial name
- NCT01157806
- Testing
- short course of palliative radiotherapy
- Where
- Poland
- Volunteers
- 20 people
- Sponsor
- Maria Sklodowska-Curie National Research Institute of Oncology
Rectal Neoplasms
Study of Postoperative Concurrent Chemo-radiation With Capecitabine in Elderly Rectal Cancer Patients
The purpose of this study is to seek the proper dose of capecitabine in post-operative concurrent chemotherapy for stage II/III elderly rectal cancer patients receiving radical surgery, and evaluate the toleration of this…
- Trial name
- NCT01268943
- Testing
- Capecitabine
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Chinese Academy of Medical Sciences
Inoperable or Recurrent Rectal Cancer
A Phase-II Study Of TOMUDEX Plus Radiotherapy In Subject With Inoperable or Recurrent Rectal Cancer
The pilot study is designed to investigate the value of Neo-adjuvant Tomudez in combination with radiotherapy in patients with inoperable or recurrent rectal cancer in terms of response rate and increasing the resectability of…
- Trial name
- TOMUDEX (NCT00590278)
- Testing
- Tomudex, Radiotherapy, Haematology
- Where
- Turkey (Türkiye)
- Volunteers
- 49 people
- Sponsor
- AstraZeneca
Metastatic Colorectal Cancer
A Clinical Trial of Durvalumab and Tremelimumab, Administered With Radiation Therapy or Ablation in Patients With Colorectal Cancer
The purpose of this study is to test the safety and effectiveness of two investigational drugs (drugs that are not currently approved by the FDA) given in combination with radiation therapy or ablation.
- Trial name
- NCT03122509
- Testing
- durvalumab, tremelimumab, Radiotherapy (RT)
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Colorectal Neoplasms
SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cancer
This phase II trial studies how well stereotactic body radiotherapy (SBRT) followed by a combination of an immune checkpoint inhibitor (sintilimab), bevacizumab, and trifluridine/tipiracil (TAS-102) works as third-line treatment…
- Trial name
- BEST (NCT07535632)
- Testing
- SBRT, Sintilimab, Bevacizumab
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Shanghai Zhongshan Hospital
Metastatic Colorectal Cancer
The Combination of Fruquintinib, Tislelizumab and Stereotactic Ablative Radiotherapy in Metastatic Colorectal Cancer(RIFLE)
This is a prospective, single-center, single-arm phase II clinical trial.This study aims to evaluate the safety and tolerability of stereotactic ablative radiotherapy (SABR) in combination with Fruquintinib and Tislelizumab, and…
- Trial name
- NCT04948034
- Testing
- Stereotactic Ablative Radiotherapy (SABR), Fruquintinib, Tislelizumab
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Fudan University
Low Anterior Resection Syndrome, Radiotherapy
Development and Validation of The Post-RT LARS Prediction Model (PORTLARS)
Bowel dysfunction is common after a restorative rectal cancer resection. Neoadjuvant radiotherapy is an influential factor that impairs bowel function and quality of life.
- Conditions
- Low Anterior Resection Syndrome, Radiotherapy, Rectal Cancer
- Trial name
- PORTLARS (NCT05129215)
- Testing
- Questionnaire
- Where
- China
- Volunteers
- 901 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Rectal Cancer
Combination of Oxaliplatin, Capecitabine, and Celecoxib With Concurrent Radiation for Rectal Cancer
A combination of chemotherapy and radiation is often used to treat rectal cancer patients before surgery in an effort to shrink the tumor and make it easier to remove as well as to help increase the chances of sphincter-sparing…
- Trial name
- NCT00250835
- Testing
- Chemotherapy, Celecoxib, and Radiation
- Where
- 3 sites in United States
- Volunteers
- 38 people
- Sponsor
- New Mexico Cancer Research Alliance
Rectal Cancer
Preoperative Short-Course Radiation Therapy With PROtons Compared to Photons In High-Risk RECTal Cancer (PRORECT)
To investigate a potential toxicity benefit of preoperative radiation therapy with protons compared to conventional photon beam radiation therapy in patients with locally advanced rectal cancer.
- Trial name
- PRORECT (NCT04525989)
- Testing
- Radiation therapy
- Where
- 9 sites in Sweden
- Volunteers
- 254 people
- Sponsor
- Alexander Valdman
Colorectal Cancer
Bortezomib, Fluorouracil, and External-Beam Radiation Therapy in Treating Patients With Stage II, Stage III, or Stage IV Rectal Cancer
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00280176
- Testing
- bortezomib, fluorouracil, radiation therapy
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Rectal Cancer, Neoplasm Metastasis
Study of Panitumumab Given First With Capecitabine and Oxaliplatin (CAPOX) and Then With Capecitabine and Radiation of the Pelvis for Treatment of Patients With Rectal Cancers That May or May Not Have Spread Beyond the Rectum
Panitumumab is a monoclonal antibody. It works by attaching to a protein called epidermal growth factor receptor found on normal and cancer cells.
- Trial name
- NCT00346099
- Testing
- Panitumumab with capecitabine and oxaliplatin (CAPOX) followed by, Panitumumab with capecitabine and radiation
- Sponsor
- NSABP Foundation Inc
Rectal Cancer, Advanced Stage Colorectal Cancer
SCRT VS LCRT Followed by PD-L1 Inhibitor Plus CAPEOX as TNT in Patients With LARC
This is a multicenter, cohort, prospective study to evaluate the efficacy and safety of Adebrelimab combined with radiotherapy and chemotherapy as preoperative neoadjuvant therapy for patients with locally advanced rectal cancer.
- Conditions
- Rectal Cancer, Advanced Stage Colorectal Cancer, Radiotherapy
- Trial name
- NCT07284992
- Testing
- short-term radiotherapy combined with Adebrelimab and capox, long-term radiotherapy combined with Adebrelimab and capox
- Where
- China
- Volunteers
- 208 people
- Sponsor
- Shandong Provincial Hospital
Colon Rectal Cancer Adenocarcinoma, Peritoneal (Metastatic) Cancer
FAPI-Guided Radiotherapy With Cadonilimab and Standard Chemotherapy for Colorectal Peritoneal Metastasis: A Phase III Randomized Controlled Trial (TORHC-PM02)
The goal of this clinical trial is to test whether adding targeted radiation plus cadonilimab immunotherapy to standard second-line chemo works better for adults with colorectal cancer only spread to the peritoneum, and check how…
- Conditions
- Colon Rectal Cancer Adenocarcinoma, Peritoneal (Metastatic) Cancer, Second-line Treatment, Radiation Therapy
- Trial name
- TORCH-PM02 (NCT07815834)
- Testing
- Second-Line Chemotherapy, Radiation Therapy, Cadonilimab (AK104)
- Where
- China
- Volunteers
- 198 people
- Sponsor
- Fudan University
Rectal Carcinoma
Resource-Sparing Curative Treatment for Rectal Cancer
This is a prospective, multicentre, randomized clinical trial comparing two different neo-adjuvant radiation-based strategies prior to intended surgery for locally advanced adenocarcinoma of the rectum.
- Trial name
- NCT01459328
- Testing
- Radiotherapy
- Where
- 12 sites in Algeria, Brazil and 9 more
- Volunteers
- 350 people
- Sponsor
- International Atomic Energy Agency
Locally Advanced Rectal Cancer
MR-guided Adaptive Radiotherapy Combined With PD-1 Antibody and CAPOX for Locally Advanced Rectal Cancer
NeoPulsar is a prospective, randomized phase II trial. 46 LARC (T3-4/N+M0, distance from anal verge ≤12cm) patients will be treated with MR-guided adaptive radiotherapy (30Gy/6Fx) combined with 6 cycles of Toripalimab and CAPOX.
- Trial name
- NCT06840665
- Testing
- PD-1 antibody, Oxaliplatin, Capecitabine
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Fudan University